CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling

Tao Wang(Tongji Hospital), Ke Chen(Merck & Co., Inc., Rahway, NJ, USA (United States))
Oncotarget
September 25, 2014
Cited by 66


Related Papers